Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects. Treatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.

NCT Number	NCT07449754
Lead Sponsor	Hanmi Pharmaceutical Company Limited
Conditions	Advanced or Metastatic Melanoma
Enrollment	45 participants
Start Date	2026-02-12
Primary Completion	2029-09 (estimated)
Study Completion	2030-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-04